Becton Dickinson and Co (NYSE:BDX) – Investment analysts at William Blair decreased their Q1 2020 earnings per share estimates for shares of Becton Dickinson and in a research note issued to investors on Tuesday, November 5th. William Blair analyst B. Weinstein now anticipates that the medical instruments supplier will post earnings of $2.64 per share for the quarter, down from their previous estimate of $3.00. William Blair also issued estimates for Becton Dickinson and’s Q2 2020 earnings at $3.14 EPS, Q3 2020 earnings at $3.29 EPS, Q4 2020 earnings at $3.66 EPS and FY2020 earnings at $12.50 EPS.
Other equities analysts have also recently issued reports about the company. Piper Jaffray Companies reduced their target price on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. ValuEngine cut Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Morgan Stanley boosted their target price on Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 16th. Finally, Wells Fargo & Co reduced their target price on Becton Dickinson and from $290.00 to $285.00 and set an “outperform” rating on the stock in a research note on Wednesday. Five research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $266.09.
Shares of BDX traded up $0.22 during mid-day trading on Friday, hitting $244.79. 1,491,912 shares of the company’s stock traded hands, compared to its average volume of 1,173,922. The company has a quick ratio of 0.67, a current ratio of 1.19 and a debt-to-equity ratio of 0.85. Becton Dickinson and has a 1 year low of $208.62 and a 1 year high of $264.74. The firm has a market capitalization of $66.59 billion, a P/E ratio of 20.96, a PEG ratio of 1.62 and a beta of 1.09. The business’s 50-day moving average price is $251.93 and its 200-day moving average price is $246.89.
Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.30 by $0.01. Becton Dickinson and had a return on equity of 15.51% and a net margin of 6.84%. The firm had revenue of $4.58 billion for the quarter, compared to analysts’ expectations of $4.57 billion. During the same period in the previous year, the firm earned $2.93 earnings per share. The business’s revenue was up 4.1% compared to the same quarter last year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in BDX. Morgan Stanley grew its stake in shares of Becton Dickinson and by 66.7% in the second quarter. Morgan Stanley now owns 4,887,187 shares of the medical instruments supplier’s stock worth $1,231,621,000 after acquiring an additional 1,955,095 shares during the last quarter. Nuveen Asset Management LLC grew its stake in shares of Becton Dickinson and by 12,995.3% in the second quarter. Nuveen Asset Management LLC now owns 1,429,875 shares of the medical instruments supplier’s stock worth $360,343,000 after acquiring an additional 1,418,956 shares during the last quarter. Thoroughbred Financial Services LLC grew its stake in shares of Becton Dickinson and by 25,302.2% in the second quarter. Thoroughbred Financial Services LLC now owns 990,940 shares of the medical instruments supplier’s stock worth $99,094,000 after acquiring an additional 987,039 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Becton Dickinson and by 33.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 2,152,328 shares of the medical instruments supplier’s stock worth $544,452,000 after acquiring an additional 543,512 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Becton Dickinson and by 2.3% in the second quarter. Vanguard Group Inc. now owns 23,018,011 shares of the medical instruments supplier’s stock worth $5,800,769,000 after acquiring an additional 520,350 shares during the last quarter. 84.29% of the stock is currently owned by hedge funds and other institutional investors.
In other news, EVP Alexandre Conroy sold 9,829 shares of the stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $255.06, for a total value of $2,506,984.74. Following the sale, the executive vice president now directly owns 16,535 shares of the company’s stock, valued at $4,217,417.10. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Vincent A. Forlenza sold 11,532 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $260.38, for a total value of $3,002,702.16. Following the completion of the sale, the chief executive officer now directly owns 218,671 shares in the company, valued at $56,937,554.98. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 32,174 shares of company stock worth $8,354,013. 0.12% of the stock is owned by insiders.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Further Reading: Cost of Equity For A Business, Investors
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.